Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Core Viewpoint - Immuneering Corporation is set to be added to the Nasdaq Biotechnology Index, effective prior to market open on December 22, 2025, highlighting its growing recognition in the biotechnology sector [1]. Company Overview - Immuneering Corporation is a late-stage clinical oncology company focused on developing innovative cancer treatments, specifically a new category of medicines known as Deep Cyclic Inhibitors [3]. - The lead product candidate, atebimetinib, is an oral medication designed to improve durability and tolerability for various cancer types, including pancreatic cancer, and is expected to enter a Phase 3 trial in mid-2026 [3]. Nasdaq Biotechnology Index (NBI) Details - The NBI tracks the performance of biotechnology and pharmaceutical companies listed on the Nasdaq Stock Market, with specific eligibility requirements such as minimum market capitalization and average daily trading volume [2]. - The index is evaluated annually in December and employs a modified capitalization-weighted methodology for its calculations [2].